SCHEMBL13199129

SCHEMBL13199129

O=C(Cc1cccc(O)c1)NNC(=O)c1cccc(O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
KDM4E B2RXH2 3/20 0.57
EGLN2 Q96KS0 1/20 0.54
HTT P42858 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
POLB P06746 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
LMNA P02545 1/20 0.48
HSP90AA1 P07900 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PLAU P00749 1/20 0.48
ELANE P08246 1/20 0.48
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
NLRP3 Q96P20 1/20 0.47
CTBP2 P56545 1/20 0.46
CA12 O43570 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13199231 0.92 TDP1 (0.62) ALDH1A1KDM4EHTTTDP1POLB
SCHEMBL13199201 0.90 NPC1 (0.55) ALDH1A1KDM4EEGLN2HTTTDP1
SCHEMBL13199145 0.90 SMN1; SMN2 (0.62) ALDH1A1KDM4EHTTTDP1POLB
SCHEMBL13199210 0.90 NPC1 (0.51) ALDH1A1KDM4EEGLN2HTTTDP1
SCHEMBL13199164 0.90 KMT2A (0.60) ALDH1A1KDM4EHTTTDP1POLB
SCHEMBL13199110 0.89 KDM4E (0.55) ALDH1A1KDM4EHTTTDP1POLB
SCHEMBL13199199 0.89 NLRP3 (0.56) ALDH1A1KDM4EHTTTDP1POLB
SCHEMBL14098240 0.87 KDM4E (0.45) ALDH1A1KDM4EEGLN2HTTTDP1
SCHEMBL13199234 0.86 TLR7 (0.53) ALDH1A1HTTPOLBMEN1KMT2A
SCHEMBL13199236 0.86 ALDH1A1 (0.66) ALDH1A1POLBMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767716-B2 Acyl hydrazines as kinase inhibitors, in particular for SGK MERCK PATENT GMBH (DE) 2010-08-03 US disclosed
US-7767716-B2 Acyl hydrazines as kinase inhibitors, in particular for SGK MERCK PATENT GMBH (DE) 2010-08-03 US disclosed
EP-1866280-B1 ACYL HYDRAZIDES AS KINASE INHIBITORS, IN PARTICULAR FOR SGK MERCK PATENT GMBH (DE) 2008-08-13 EP disclosed
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk MERCK PATENT GMBH (DE) 2008-07-10 US disclosed
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk MERCK PATENT GMBH (DE) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167380-A1 Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk SGK1, AGK, SGK2 ALDH1A1 1664/4885KDM4E 1312/4885EGLN2 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.